Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 03:56pm CET

JOHANNESBURG - Aspen yesterday welcomed the Competition Commission's decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commission’s initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts “due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable”.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. “In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany,” the commission said.

“It is, therefore, unlikely that the price charged by Equity could pass the test for excessive pricing.” The commission, however, alleged that Roche and Genentech had engaged in excessive pricing, price discrimination and exclusionary conduct in the provision of breast cancer medicine in South Africa, adding that breast cancer treatment was unaffordable in South Africa.

The commission said investigations on Pfizer for excessive pricing of lung cancer medication in South Africa would continue. The drug maker was the only provider of a lung cancer treatment medication, known asXalkori (crizotinib), in South Africa. The body also alleged that lung cancer treatment in South Africa was unaffordable.

Aspen shares fell 0.01 percent on the JSE yesterday to close at R304.75 a share.


(c) Cape Community 1999 - 2017 Independent Newspapers (Pty) Limited. All rights strictly reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER 0.55% 36.78 Delayed Quote.0.99%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
03/17ROCHE : Federal Contracts Awarded to Companies in Indiana (March 17)
03/17ROCHE : Federal Contracts Awarded by Federal Agencies in North Dakota (March 17)
03/16KNOW ABOUT CERVICAL CANCER MARKET IN : New Research: Cervical Cancer Market &nda..
03/16ROCHE : Q-- 6 month Bridge ROCHE - DES MOINES
03/16ROCHE : Q-- 6 month Bridge ROCHE - IOWA CITY
03/16ROCHE : $1.31 Million Federal Contract Awarded to Roche Diagnostics
03/16ROCHE : Vintage Drawer Pulls and Handles Bring High Aesthetics to Every Home
03/16ROCHE : $432,000 Federal Contract Awarded to Roche Diagnostics
03/16ROCHE : $375,000 Federal Contract Awarded to Roche Diagnostics
03/15FOUNDATION MEDICINE : Tango Therapeutics Expands Board of Directors with the Add..
More news
News from SeekingAlpha
03/18ETF MONTH #4 : Developed Markets (Ex-North America) With EFA. But Is There A Bet.. 
03/183 THINGS IN BIOTECH, MARCH 17 : Janssen's Bladder Breakthrough, MorphoSys' Alzhe.. 
03/16Key events next week - healthcare 
03/14Updating Our Thoughts On Celgene 
03/12ROCHE : Review, With Focus On Cancer Vaccines (Part 2 Of 2) 
Financials ( CHF)
Sales 2018 55 185 M
EBIT 2018 19 152 M
Net income 2018 11 880 M
Debt 2018 4 190 M
Yield 2018 3,94%
P/E ratio 2018 15,31
P/E ratio 2019 14,58
EV / Sales 2018 3,52x
EV / Sales 2019 3,34x
Capitalization 190 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 267  CHF
Spread / Average Target 21%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-10.73%201 801
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
MERCK AND COMPANY-1.07%148 965
AMGEN8.25%136 727